Bioengineering lungs: An overview of current methods, requirements, and challenges for constructing scaffolds

Shahad Shakir1, Tillie Louise Hackett2,3 and Leila B. Mostaço-Guidolin4*

1Department of Mechanical and Aerospace Engineering, Carleton University, Ottawa, ON, Canada, 2Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada, 3Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, 4Department of Systems and Computer Engineering, Carleton University, Ottawa, ON, Canada

Chronic respiratory diseases remain a significant health burden worldwide. The only option for individuals with end-stage lung failure remains Lung Transplantation. However, suitable organ donor shortages and immune rejection following transplantation remain a challenge. Since alternative options are urgently required to increase tissue availability for lung transplantation, researchers have been exploring lung bioengineering extensively, to generate functional, transplantable organs and tissue. Additionally, the development of physiologically-relevant artificial tissue models for testing novel therapies also represents an important step toward finding a definite clinical solution for different chronic respiratory diseases. This mini-review aims to highlight some of the most common methodologies used in bioengineering lung scaffolds, as well as the benefits and disadvantages associated with each method in conjunction with the current areas of research devoted to solving some of these challenges in the area of lung bioengineering.

KEYWORDS
bioengineered lungs, scaffolds, recellularization, acellular lung scaffolds, artificial lung scaffolds, bioreactors, 3D bioprinting, electrospinning

1 Introduction

Chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer combined are the third leading cause of death worldwide (De Santis, 2021). Over, four million people die prematurely from lung diseases per year, and they are predicted to continue to increase over the upcoming years (GBD 2015 Mortality and Causes of Death Collaborators, 2016). Currently, there is no cure for these diseases and lung transplantation (LTX) remains the only option for individuals with end-stage lung failure. Despite the improvement in organ preservation techniques, and specifically ex vivo lung perfusion (EVLP), alternative options are urgently required to increase available tissues for transplantation and close the gap in
this clinical need (Dorrello et al., 2017; Chan et al., 2020). A novel research area that can assist with addressing this issue is bioengineered lung tissues. Although it remains a challenge to achieve a fully functional bioengineered lung that could be transplanted, new techniques are being explored to fabricate functioning ex vivo engineered lung tissues with proper gas exchange properties. These engineered models can be used as tools to aid in the development of new therapeutics and to understand lung physiology, cell-cell and cell-matrix interactions in disease models, and eventually increase tissue availability for lung transplantation (Gilpin et al., 2018).

The intricate native 3D architecture of the lung must be maintained, thus decellularized biological scaffolds from animal or human organs have become extremely useful templates for lung engineering (Wanczyk et al., 2021). The use of scaffolds eliminates the need to reconstruct the highly complex extracellular matrix (ECM) within the airways, parenchyma and vascular networks, offering an ideal acellular structure for seeding and recellularization. However, it is unknown to what extent the tissue and ECM components are preserved during decellularization, which is vital for the functionality of the bioengineered lung (De Santis et al., 2018; De Santis, 2021). Alternatively, synthetic lung scaffolds are another option to acellular scaffolds, where both synthetic and natural polymers can be used in the manufacturing process. Several approaches have been studied in manufacturing synthetic lungs such as 3D bioprinting, cryogelation, solvent-casting, and particulate-leaching techniques (De Santis et al., 2018; Eltom et al., 2019). In this mini-review, we aim to discuss recent advances and emerging technologies used in lung scaffolds bioengineering, as summarized in Figure 1. We also discuss some of the major requirements and challenges for future advancements.

2 Synthesizing biological (acellular) lung scaffolds

The limited accessibility of lung tissues available for LTX remains a major issue, and bioengineered tissues have the potential to bridge this gap. Bioengineered tissues rely on the incorporation of cells with biodegradable and biocompatible structures, known as scaffolds. Scaffolds mimic the extracellular matrix (ECM), by providing structural support, biological, chemical, and mechanical cues that influence the development of new tissues. Scaffolds act as a template to permit the transport of liquids, nutrients, gases, promote cell-cell interactions and ECM deposition, while reducing the risk of immunogenicity and proinflammatory responses through biocompatible and biodegradable properties (Prakash et al., 2015; Nikolova 2019; Nikolova and Chavali, 2019).

Despite the fact that lung tissue engineering efforts have typically trailed behind those of other organs, significant new developments using natural and synthetic scaffolds have been made. It is essential to investigate the characteristics necessary while choosing a scaffold to engineer a tissue. Properties such as strength, elasticity, nutrient transfer, cellular remodeling, and geometry should allow for proper tissue functionality (Nichols et al., 2013). Current approaches in the pre-clinical phase involve the use of decellularized biological and artificial lung scaffolds, seeded with cells sourced from the transplant recipient to promote tissue regeneration (Prakash et al., 2015).

2.1 Recapitulating biological lung scaffolds

The lung is a complex organ containing at least 40 distinct types of cells. These cells interact with an extracellular matrix (ECM), which is made up of different regional combinations of ECM proteins and glycosaminoglycans (e.g., proteoglycans and hyaluronan) that act as a scaffold to not only provide structure, but also help direct repair and regeneration after injury (Franks et al., 2008; Burgstaller et al., 2017). The use of biological lung scaffolds helps in retaining the complex ECM and scaffold structure, making this method a promising technique for lung bioengineering. Researchers have been exploring transplantation in animal models, and successful transplantation using acellular scaffolds in rodent and porcine models has been achieved (Tsuchiya et al., 2014; Wanczyk et al., 2021). To use these acellular scaffolds, a decellularization process that removes cells and cellular materials from the tissue or organ is required. Decellularization techniques leave an intact 3D scaffold and ECM composition, which can later be recellularized with necessary cells to carry proper functions (Gilpin and Yang, 2017; Mendibil et al., 2020; Wanczyk et al., 2021). Sections below will dive deeper into decellularization and recellularization techniques.

2.1.1 Decellularization techniques

The lung decellularization process is carried out using chemical and physical methods, or a combination of both. Chemical methods include using genzymatic agents, and detergents. Ionic and nonionic detergent-based solutions such as sodium dodecyl sulfate (SDS), sodium deoxycholate (SDC), and Triton X-100, are the most used to wash away cell debris (Wallis et al., 2012; Lin et al., 2013), but each method possesses side effects. SDS is cytotoxic, and it requires an extensive washing process, it can also denature proteins, and the residual matrix may contain nuclear and cytoplasmic waste (Gilpin and Yang, 2017; Mendibil et al., 2020). SDC can cause aggregation of DNA when used without DNase, however, it is a simple, versatile and nondisruptive method for tissue decellularization (Meezan et al., 1975; Gilpin and Yang, 2017). Triton X-100 is not recommended for decellularization of ECM, where lipids and glycosaminoglycans (GAGs) are important for cell specific functions, but it is less damaging to the structure of tissues.
than ionic surfactants (Gilpin and Yang, 2017; Mendibil et al., 2020).

Alternatively, physical methods include the use of osmotic shock, sonication, and freezing-thawing to break the cell membrane (Mendibil et al., 2020; Rabbani et al., 2021). Hypotonic and hypertonic solutions are used to deliver an osmotic shock kills cells through cell explosion, and it releases the cell waste to the matrix. It is important to note that the cell waste released should be managed and is considered in the design of the decellularization procedure (Reing et al., 2010; Mendibil et al., 2020). The sonication and agitation methods are commonly used to facilitate chemical agent infiltration and to induce cell lysis, however, the entire process can induce significant damage to the ECM. Lastly, freezing methods utilize crystals that are created in the freezing process, which are employed to damage cell membranes. The advantage of this method includes maintaining the ECM proteins, and mechanical properties, but it is unknown what degree the ECM protein structure is compromised (Gilpin and Yang, 2017; Mendibil et al., 2020).

These methods are known to retain most of the macro and microstructure of the lung and leave all ECM components intact. By unaffected the ECM structure, it is possible to aid the promotion of cell proliferation after recellularization, as it contains proteins and biochemical cues that would direct cells and facilitate cell communication (De Santis et al., 2018; Young 2019). However, it is not known to what degree the microarchitectural, airway and vascular systems, and ECM components (such as collagen, elastin, fibronectin, and GAGS) have been preserved, leading to possible tissue functionality limitations (Balestrini, Niklason, 2015).

The mechanical properties and biomimicry of hydrogels are crucial to promote tissue growth. Lung tissues enzymatically solubilized have been shown to be a promising method to obtain dECM (decellularized ECM) to coat transwell inserts to enhance cell adhesion and growth (Barreiro Carpio et al., 2021). This work provided a complete investigation of how different dECM solutions affects cell proliferation and viability on hydrogels.

A recent study by Skolasinski and Panoskaltsis-Mortari suggests leaving the vasculature intact while only decellularizing the airway epithelium can benefit in preserving some architecture and ECM components (Skolasinski and Panoskaltsis-Mortari, 2018; Wanczyk et al., 2021). Additionally, Obata et al. used natural soap, potassium laurate, as a decellularization detergent that was found to be less abrasive and showed to be effective in removing cellular components and cells while preserving the 3D lung architecture better (Obata et al., 2019). Lastly, to promote cellular adhesion and differentiation, scaffolds can be replenished with ECM proteins and coated with agents that improve vascularization in organs (Shojaie et al., 2015; Young et al., 2019; Yuan et al., 2019; Uhl et al., 2020; Wanczyk et al., 2021).

It is important to also highlight that the procedure does not consider cytocompatibility related to residual cell debris and unremoved decellularization agents in the tissue (Gilpin and Wagner, 2018). Lastly, an ideal decellularization protocol has not been found yet, wherein published literature, different studies state different administrative ways, solution volumes, detergent concentration, and length of exposure. This may influence the recellularization process and the eventual bioengineered tissue (Balestrini et al., 2015; Colvin and Yeage, 2015) Therefore, more research is required to standardize the current decellularization process Figure 1.

2.1.2 Recellularization process: An overview

The recellularization process involves repopulating cells into the acellular scaffold, to promote cell attachments, proliferation, and migration that would allow for organ regeneration (Ahmed et al., 2021) Autologous cells derived from the patient are considered an ideal source as they can reduce adverse immunological response and the need for long-term immunosuppressive medications (Hillebrandt et al., 2019). Common cell types that have been successfully used in the recellularization of acellular lung scaffolds include induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), and lung-derived progenitor cells (Wagner et al., 2013; Weiss et al., 2013; Tsuchiya et al., 2014; Scarritt et al., 2015). iPSCs cells that are derived from programmed adult somatic cells can be differentiated into the epithelial cells, making them an ideal seeding source and show promise in the development of lung-specific cells (Prakash et al., 2015; Aboul-Soud et al., 2021). While candidates for stem/progenitor cells include alveolar progenitor cells (AEPCs) that are isolated from human lungs, they require certain cues that are secreted by the ECM, which emphasizes the need for a decellularization protocol that retains important ECM components (Tsuchiya et al., 2014; Prakash et al., 2015).

Although multiple studies show the potential of these different cell sources to recellularize a lung scaffold, the challenge remains in choosing appropriate cell types, quantities, and combinations to achieve full tissue functionality (Echeverria Molina et al., 2021). Emerging data obtained from advanced single-cell analyses and multi-omics approaches, combined with 3D image analyses can enhance the biofabrication of functional lung tissues, where data regarding cell identity, localization, and abundance can be evaluated. Furthermore, trajectory inference methodologies can be used to infer the sequence of lung cells, allowing to engineer mature lung types with greater capabilities to restore tissue structure and functionality (Jackson et al., 2020; Wanczyk et al., 2021).

It is important to note that when considering the sources of the biological scaffold, the donor tissue does not have to be of human origin, and tissues can be sources from similar species such as porcine and non-human primates (De Santis et al., 2018; Ribitsch et al., 2020). Using non-human scaffolds provides a uniform scaffold for lung bioengineering, which reduces some of the limitations that human lungs possess, however, ethical and health issues with animal scaffolds remain a problem (Nichols
et al., 2013). Although acellular biological lungs show great potential, this approach is challenging due to the shortage of suitable human lungs available, as well as the potential heterogeneity and xenogeneity issues, making an alternative method extremely needed (Mohgan et al., 2022, De Santiset al., 2018).

3 Artificial lung scaffolds

Despite the advances that have been made regarding using biological (acellular) lung scaffolds, their heterogeneity and potential xenogeneic concerns make this technique difficult to scale-up in a repeatable and regulated manner (Chan and Leong, 2008). Artificial, or synthetic, lung scaffolds can be utilized instead of acellular scaffolds, where both synthetic and natural polymers are typically used in the manufacturing. One advantage of using synthetic materials to biofabricate scaffolds is the ability to tailor their biological and physical properties to achieve a desirable scaffold (Nikolova and Chavali, 2019; Matai et al., 2020). Although researchers have explored using methods such as 3D bioprinting, cryogelation, solvent-casting, and particulate-leaching techniques to engineer tissues, challenges are still present when the goal is to generate functional lung tissues (De Santis et al., 2018; Eltom et al., 2019; Xie et al., 2020). Limitations include the lung’s complex airway branching structure, and the challenge of low biocompatibility and hemocompatibility, which are the ability of being compatible with a living tissue and with blood, respectively (Tebyanian et al., 2019). To date, many techniques have been investigated to artificially engineer separately tracheal, bronchial, and parenchymal lung tissues. Specifically, tracheal lung tissue engineering has been studied more extensively due to the

**FIGURE 1**
Lung tissue scaffolds can be bioengineering in different ways. (A) Biological lung scaffolds can be obtained from humans and animals, where they are decellularized using enzymatic agents and detergents to remove cellular components and achieve an ECM-based, acellular scaffold. (B) Artificial scaffolds can be manufactured based on a variety of methods (e.g., 3D bioprinting, electrospinning), utilizing synthetic biomaterials, cells, and bioinks. (C) By combining biological components such as cells and ECMs, hybrid scaffolds can be manufactured in combination with biocompatible materials which provide the necessary structure and mechanical proprieties to promote cell proliferation, adhesion and viability. Figure designed by Freepik with elements from flatcon.com.
| Applications | Limitations | Selected references |
|--------------|-------------|---------------------|
| **Biological Lung Scaffolds** | | |
| Overview | Offers an ideal acellular structure for seeding and recellularization. | Donor shortages. | Tsuchiya et al. (2014), Wanczyk et al. (2021), Chan and Leong, (2008). |
| | Aid in retaining the complex biological ECM and scaffold structure | Difficult to scale up in a repeatable and regulated manner due to many donated lungs do not meet the criteria for transplantation | |
| | | | |
| **Decellularization** | Removes cells and cellular materials from the tissue or organ | Not known to what degree is macro and microstructure is preserved | De Santis et al. (2018), Young (2019), Barreiro Carpio et al. (2021), Ballestini and Niiklason, (2015), Gilpin and Wagner, (2018), Calvin and Yang, (2015), Ballestini et al. (2015). |
| | Retain most of the macro and microstructure of the lung | Procedure does not consider cytocompatibility related to cell debris and unremoved decellularization agents | |
| | Leave ECM intact, improves cell proliferation and recellularization | No standard decellularization protocol available yet | |
| **Recellularization** | Repopulating scaffolds with cells, to promote cell attachment, proliferation, and migration to carry out proper functions and organ regeneration | Challenge remains in choosing appropriate cell types, quantities, and combinations. | Ahmed et al. (2021), Echeverría-Molina et al. (2021), Tsuchiya et al. (2014), Prakash et al. (2015) |
| | | No standard recellularization protocol available yet | |
| **Artificial Lung Scaffolds** | | |
| Overview | Helps with organ shortages issues. | Lung’s complex hierarchical structure makes it difficult to biofabricate a scaffold. | Nikolova and Chavali, (2019), Matai et al. (2020), Xie et al. (2020), Elliot et al. (2019), De Santis et al. (2018), Tebyanian et al. (2019), Ling et al. (2014), Andrade et al. (2007), Singh et al. (2013), Wilkinson et al. (2017) |
| | Possible to tailor their biological and physical properties to achieve a desirable scaffold. | Scaffold lack the vasculature and gas exchanges characteristics required for a functional lung tissue. | |
| **3D Bioprinting** | Allow for custom-made 3D designs. | Challenge in choosing appropriate manufacturing methods, that allow bioprinting at a microscale resolution to achieve key features of lung tissues. | Rider et al. (2018), Mahfouzi et al. (2021a), Xie et al. (2020), Barreiro Carpio et al. (2021), Frejo, Grande, (2019), Galliger et al. (2019), Grigoryan et al. (2019), Suki and Bates, (2008), Ozbolat and Yu, (2013), De Santis et al. (2021). |
| | Scaffolds can be bioprinted with growth factors or drugs that can be released, expediting tissue formation. | The lack of an appropriate commercial bioink that mimics the true ECM-like elements. | |
| **Electrospinning** | Electrosyn scaffolds can be fabricated to any size, and fiber parameters. | Challenges in controlling geometry of the scaffolds, damage to encapsulated cells, and insufficient control of cell patterning. | Jun et al. (2018), De Santis et al. (2018), Young et al. (2017), Asadian et al. (2020), Abbasi et al. (2014), Owida et al. (2022), Persano et al. (2013). |
| | Capable of allowing ideal cell interactions, adherence, proliferation, migration, and differentiation with an appropriate plasma treatment | Further properties such as mechanical strength and potential toxicity need to be further studied | |
| | Simple, low-cost, and is an adaptable technology | | |
| **Bioreactors** | Provide controlled and prespecified environmental settings, allowing the needed biological processes to occur to support cells | Achieving a uniform temperature across the chamber | Farré et al. (2018), Mahfouzi et al. (2021b), Garcia-Garza et al. (2020). |
| | Expose re-seeded scaffolds to physical and biochemical stimuli | Achieving a sterile environment | |
| | | Achieving proper pH control and waste removal | |
trachea’s architecture and tubular structure (Jungebluth et al., 2011; Chang et al., 2014; Jungebluth et al., 2014; Crowley et al., 2015; De Santis et al., 2018).

Promising prototypes show that epithelialisation and vascularisation of the grafts can be achieved through different procedures. On the other hand, there is a lack of research surrounding 3D-bioprinting and organoids techniques for parenchymal lung tissues. Techniques such as foaming, porogen-solvent, and self-assembly of microspheres show great promise, but the fabricated scaffold lacks the vasculature and gas exchanges characteristics required for functional lung tissue (Andrade et al., 2007; Singh et al., 2013; Ling et al., 2014; Wilkinson et al., 2017; De Santis et al., 2018). Below we discuss the various techniques that have been used to develop artificial lung scaffolds Table 1.

3.1 Potential manufacturing methods to generate artificial scaffolds for lung tissue engineering

Different manufacturing methods have been researched for manufacturing porous structures for tissue engineering. Methods such as electrospinning, 3D bioprinting, cryogelation, solvent-casting, and particulate-leaching techniques have been used (De Santis et al., 2018; Eltom et al., 2019; Xie et al., 2020). Particularly in terms of lungs, electrospinning and 3D bioprinting have been gaining more attention recently. Electrospinning has emerged as a promising method and is considered to be effective in producing porous structures composed of thin, nano-fibers, that are capable of providing enough support for the cell attachments, proliferation, and differentiation (Persano et al., 2013; Owida et al., 2022). However, challenges such as geometry control, cell damage, and insufficient control of cell patterning remain an issue (Jun et al., 2018).

On the other hand, 3D Bioprinting has emerged as a promising source for bioengineering tissues. Using 3D bioprinting allows researchers to create tissues mimicking natural tissues, that can aid in studying in-vitro models and eventually be used in tissue transplantation (Kolesky et al., 2016; Feinberg and Miller, 2017; Zhu et al., 2017). Despite its great promise, 3D printing a fully functional lung structures remain a challenge and is beyond current capabilities. Research is also currently limited in regard to attempts involving 3D bioprinting of lung tissues (Barreiro Carpio et al., 2021). Below, these manufacturing methods are explained in more depth.

3.1.1 Electrospinning

Electrospinning has emerged as one of the methods used to produce fibrillar scaffolds and has been extensively used to engineer the trachea scaffolds (Young et al., 2017; De Santis et al., 2018). Electrospun scaffolds can be fabricated to any size, and fiber parameters such as density, composition, and orientation can be manipulated to create a reliable ECM network (Jun et al., 2018; De Santis et al., 2018; Young et al., 2017).

It has been shown that these fabricated lung scaffolds have the ability to provide ECM fiber orientation and mechanical properties comparable to native lungs (Young et al., 2017; Nguyen-Truong et al., 2020). Electrospinning techniques are also capable of allowing ideal cell interactions and adherence, as well as cell proliferation, migration, and differentiation with an appropriate plasma treatment (Abbasi et al., 2014; Asadian et al., 2020). Moreover, to encourage successful tissue transplantation, scaffolds can incorporate growth factors or drugs that can be released, expediting tissue formation, and allowing the transplanted tissue to achieve homeostasis (Howard et al., 2008). There are many advantages of using electrospinning to create artificial scaffolds. Electrospinning is simple, low-cost, and is an adaptable technology with a great potential for developing multifunctional materials for application in tissue engineering. It has also been shown to be a valuable method to create ECM-mimicking structures, making scaffolds have identical ECM structures to those of native tissues than other conventional methods (Persano et al., 2013; Owida et al., 2022).

Although electrospinning has emerged as a favourable method used in multiple fields of tissue engineering, and shows a promising technique in artificial lung fabrication, challenges to control the geometry of the fabricated organ, damage to encapsulated cells, and insufficient control of cell patterning remains an issue, since cells must remain viable, and the constructs must preserve their structural integrity during/post printing process (Jun et al., 2018). Additionally, the vast majority of published research has been done in vitro. As a result, the composition and structure must be adjusted for in vivo applications in future research. Lastly, for ultimate clinical application, properties such as mechanical strength, cell infiltration, impediment, and potential toxicity of electrospun scaffolds need to be further studied (Owida et al., 2022).

3.1.2 3D-bioprinting

Amongst the most versatile engineering approaches that allow for custom-made 3D designs in tissue engineering is 3D-bioprinting, which has emerged as a powerful technique in producing synthetic scaffolds for organs (Rider et al., 2018). 3D bioprinting has been an attractive tool that is being explored to engineer organs with the ultimate goal of producing transplantable tissues, and in the case of the lung, for creating artificial lung scaffolds (Mahfouzi et al., 2021a). Significant progress has been made that allows for the 3D bioprinting of the trachea and bronchus, but the challenge remains in choosing appropriate manufacturing methods, that allow bioprinting at a microscale resolution to achieve...
key features of lung tissues (Frejo and Grande, 2019; Galliger et al., 2019; Xie et al., 2020). Additionally, scaffolds design criteria need to also be addressed to achieve functional tissues. The final structure must mimic that of a biological lung and should meet the geometrical and characteristics requirements. Appropriate viscoelastic and mechanical traits must allow for lung inflation, deflation, and normal blood flow (Suki and Bates, 2008; Grigoryan et al., 2019; Mahfouzi et al., 2021a). Additionally, selecting a proper bioink is a critical step in 3D bioprinting. Bioinks that provide proper properties related to mechanical strength, flexibility, biocompatibility, biodegradability, bioabsorbability, and printability are essential to achieve a functioning organ (Mahfouzi et al., 2021a). They should also have properties needed to allow for specific biological cues that guide cell growth, differentiation, and migration (Mahfouzi et al., 2021b; Doyle and O’grady, 2013). One of the limiting factors of 3D bioprinting lung scaffolds is the lack of an appropriate commercial bioink that mimics the true ECM-like elements (De Santis et al., 2021). However, recent research by De Santis et al. showed a promising proof-of-concept for bioprinting human airways using a hybrid bioink, which is composed of alginate and a natural polymer, and reinforced with ECM from decellularized tissues (rECM) (De Santis et al., 2021). It can maintain biological properties while supporting tissue growth, as well as provide bioprinted constructs that are proangiogenic, biocompatible, and support new blood vessel formation (De Santis et al., 2021).

Recreating the human lung architecture is a challenging task with a high level of difficulty. Although current technologies are still unable to achieve the level or resolution needed for a functional, 3D bioprinted lung, due to its complex vasculature and architecture, it is important to highlight key challenges that need to be addressed to achieve a transplantable organ (Barreiro Carpio et al., 2021). The alveolar epithelium and vascularization of the lung needs to be reproduced accurately, requiring a specific spatial resolution that currently is a challenge for existing bioprinters (Weibel, 2015). To add, the bronchi, bronchiole, and alveoli not only present geometrical challenges for current bioprinters, but also require cells to be deposited at certain locations to form a functional membrane. Lastly, the limited biomaterials available for the printing process present a great level of difficulty to mimic the physical properties (e.g., stiffness, elasticity, and gap permeability) of the lung, which are vital to its function during the process of breathing (Barreiro Carpio et al., 2021).

### 3.2 Bioreactors for cell expansion, differentiation, decellularization and re-cellularization

Bioreactors are critical in the bioengineering of lungs. Due to the unique lung anatomy and physiology, the use of bioreactors is crucial to biofabricate lung scaffolds, both artificial and biological. They provide controlled and prespecified environmental settings, allowing the biological processes needed to occur to support cell growth and differentiation, tissue decellularization and recellularization, and monitoring cell cultures (Farré et al., 2018; Mahfouzi et al., 2021a). They expose re-seeded scaffolds to physical and biochemical stimuli, allowing cells to undergo differentiation and regeneration within developing scaffolds. These stimuli can influence cell seeding, nutrient uptake in the medium, and mechanical forces (García-Gareta et al., 2020). Several bioreactors types exist for different applications.

Some examples include bioreactor systems for decellularization of scaffolds by perfusion and recellularization by perfusion and ventilation (Talò et al., 2020; Mahfouzi et al., 2021b). Others are systems used for large-scale cell cultures, which are composed of rotating bioreactors that differentiate epithelium cells for lung bioengineering by exposing cells to air and liquid (Ghaedi et al., 2014; Mahfouzi et al., 2021a). However, in regard to bioreactors involved in re- and decellularization of lungs, further limitations need to be addressed, such as achieving a uniform temperature across the chamber, sterile environment, pH control, and proper waste removal (Mahfouzi et al., 2021b). Lastly, ensuring adequate nutrient and oxygen supply available for the tissue is crucial. In the case of lung bioreactors, the organ should be exposed to controlled perfusion, ventilation, and gas exchange (Farré et al., 2018).

### 4 Discussion and future perspectives

Lung bioengineering requires a delicate balance between choosing the suitable scaffold material and enabling ECM function. Advantages and limitations of the different methods are summarized in Table 1. The above mentioned techniques described in this review offer a wealth of opportunities in lung bioengineering, and will lead to advancement for future transplantation. However, substantial experimental work is still needed to translate this technology into clinical practice. Ethical
and legality issues need to be addressed before starting trials in humans, which include implementing strict regulations regarding the starting biomaterials (cells and scaffolds), methodology, and reliability and availability of materials and processes used (Farré et al., 2018). In the pre-clinical stages, many ethical considerations must be considered, including appropriate reporting, distribution of results, data integrity, and ensuring that every study done is planned to generate results suitable for deciding on the next research steps. Further, challenges such as safety and efficacy, scaling the bioengineered lungs to fit the patient’s body, choosing how biological materials are regulated and distributed, and cost of manufacturing need to be addressed before moving into the pre-clinical trials phase (Farré et al., 2018; De Santis et al., 2021).

To move forward with creating transplantable tissues, procedures regarding decellularization and recellularization must be established, and a proper framework that is sufficient to fully elucidate the physiological and biochemical interactions must be developed. Additionally, prior to clinical trials, the short and long outcomes of these transplantable tissues must be studied in animal models. This will aid in establishing regulatory frameworks and good manufacturing practice (GMP) standards regarding patient safety (Taylor et al., 2014). To date, the criteria used to evaluate bioengineered lung tissue prior to clinical trials remain undefined, although using measures similar to those that are used in EVLP may be reasonable as a first step. It is vital that researchers, physicians, and regulatory authorities collaborate to build these new frameworks (Tsuij et al., 2014; Elliott et al., 2017; Mohgan et al., 2022).

In contrast, the use of acellular lung scaffolds is highly dependent on the donor material. Often, many donated lungs do not meet clinical criteria for transplantation, especially when the lungs are donated after cardiac death. Comorbidities such as chronic obstructive pulmonary disease (COPD), asthma and immunogenicity are also important factors (Tsuij et al., 2014). Future research can explore ways to improve the approaches used in donated lungs after cardiac death, which may include using bioengineering methods to generate a reproducible functional lung tissue (Chan et al., 2020).

In conclusion, the research that has been made in lung bioengineering has been used to better understand the biological process of lung repair during injury and has helped replace the need for animals to model disease (De Santis et al., 2021). The potential rewards of success in developing lung scaffolds holds great promise for patients suffering from multiple chronic pulmonary diseases. However, it clearly remains an ambitious goal to be continually tackled by multidisciplinary collaborations and team efforts amongst bioengineers, physiologists, and clinicians. Advances related to scaffold design and production, biocompatibility of materials, and the ability to maintain appropriate biomechanical properties, are only a few challenges behind the development of lung scaffolds. The development of mathematical models and techniques to improve cell viability, proliferation, adhesion at the same time once can control ECM properties, will allow the discoveries to provide stepping stones toward the development of clinically useful tissue-engineered lung.

Author contributions

Writing—original draft preparation, review and editing, SS, TH, and LBM-G. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Natural Sciences and Engineering Research Council (Discovery Grant of Canada—RGPIN-2021-04185) and Carleton University (Research Development Grant 2020/21).

Acknowledgments

The figures were created with Affinity Designer and Flaticons. Figure designed by Freepik with elements from flaticon.com.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Kolesky, D. B., Homan, K. A., Skylar-Scott, M. A., and Lewis, J. A. (2016). Three-dimensional bioprinting of thick vascularized tissues. *Proc. Natl. Acad. Sci. U. S. A.* 113 (12), 3179–3184. doi:10.1073/pnas.1521342113

Lin, Y., Wang, K., Tan, Y., Lin, H., Peng, B., and Liu, Z. (2013). Evaluation of the combinative application of SDS and sodium deoxycholate to the LC-MS-based shotgun analysis of membrane proteomes. *J. Sep. Sci.* 36 (18), 3026–3034. doi:10.1002/jss.201300413

Ling, T. Y., Liu, Y. L., Huang, Y. K., Gu, S. Y., Chen, H. K., Ho, C. C., et al. (2014). Differentiation of lung stem/progenitor cells into alveolar pneumocytes and induction of angiogenesis within a 3D gelatin–microbubble scaffold. *Biomaterials* 35 (22), 5566–5569. doi:10.1016/j.biomaterials.2014.03.074

Mahfouzi, S. H., Amoabediny, G., and Safabadi Tali, S. H. (2021a). Advances in bioreactors for lung bioengineering: From scalable cell culture to tissue growth monitoring. *Biotechnol. Bioeng.* 118 (6), 2142–2167. doi:10.1002/bit.27728

Mahfouzi, S. H., Tali, S. H. S., and Amoabediny, G. (2021b). 3D bioprinting for lung and tracheal tissue engineering: Criteria, advances, challenges, and future directions. *Bioprinting* 21, e01942. doi:10.1002/bpre.2020e01942

Mandrycky, C., Wang, Z., Kim, K., and Kim, D. H. (2016). 3D bioprinting for engineering complex tissues. *Biotechnol. Adv.* 34 (4), 422–434. doi:10.1016/j.biotechadv.2015.12.011

Matai, I., Kaur, G., Seyedsalehi, A., McClinton, A., and Laurencin, C. T. (2020). Progress in 3D bioprinting technology for tissue/organ regenerative engineering. *Biomaterials* 226, 119536. doi:10.1016/j.biomaterials.2019.119536

Meeran, E., Hylle, J. T., Brendel, K., and Carlsson, E. C. (1975). A simple, versatile, nondisruptive method for the isolation of morphologically and chemically pure basement membranes from several tissues. *Life Sci.* 17 (11), 1721–1732. doi:10.1016/0024-3205(75)90119-8

Mendibil, U., Ruiz-Hernandez, R., Retegi-Carrion, S., Garcia-Urquia, N., Olafde-Gracias, B., and Aberatagi, A. (2020). Tissue-specific cell decellularization methods: Rationale and strategies to achieve regenerative compounds. *Int. J. Mol. Sci.* 21 (15), 5447. doi:10.3390/ijms21155447

Mohgan, R., Candasamy, M., Mayuren, J., Singh, S. K., Gupta, G., Dua, K., et al. (2022). Emerging paradigms in bioengineering the lungs. *Biotechnol. Bioeng.* 9 (15), 195390. doi:10.1002/bit.27858

Murphy, S. V., and Atala, A. (2014). 3D bioprinting of tissues and organs. *Nat. Biotechnol.* 32 (8), 773–785. doi:10.1038/nbt.2958

Nguyen-Truong, M., Li, Y. V., and Wang, Z. (2020). Mechanical considerations of electrospun scaffolds for myocardial tissue and regenerative engineering. *Bioeng. (Basel, Switz.)* 7 (4), 122. doi:10.3390/bioengineering7040122

Nichols, J. E., Niles, J., Riddle, M., Vargas, G., Schlagard, T., Ma, L., et al. (2013). Production and assessment of decellularized pig and human lung scaffolds. *Tissue Eng. Part A* 19 (17-18), 2045–2062. doi:10.1089/ten.TEA.2012.0250

Nikolova, M. P., and Chavali, M. S. (2019). Recent advances in biomaterials for 3D scaffolds: A review. *Bioact. Mater.* 4, 271–292. doi:10.1016/j.bioactmat.2019.10.005

Obata, T., Tsuchiya, T., Akita, S., Kawahara, T., Matsumoto, K., Miyazaki, T., et al. (2019). Utilization of natural detergent potassium laurate for decellularization in lung bioengineering. *J. Thorac. Cardiovasc. Surg.* 157 (1), 307–315. doi:10.1016/j.jtcvs.2018.07.032

Onda, H. A., Al-Nabulsi, J. I., Alnaimat, F., Al-Ayyad, M., Turab, N. M., Al-Sharab, T., et al. (2020). Large animal models in regenerative medicine and tissue engineering complex tissues. *Ann. Biomed. Eng.* 48 (3), 1112–1126. doi:10.1007/s10439-019-02257-6

Sarkar, M. K., Bhattacharya, A., and Tripathy, N. (2015). 3D printing for tissue engineering of whole organs. *Expert Opin. Biol. Ther.* 15 (10), 879–882. doi:10.1517/14712598.2015.915301

Shakir et al. 10.3389/fbioe.2022.1011800

Tebyanian, H., Karami, A., Nourani, M. R., Motavallian, E., Barkhordari, A., and Farahzad, M. (2019). Lung tissue engineering: An update. *J. Cell. Physiol.* 234 (11), 19256–19270. doi:10.1002/jcp.28558

Talò, G., D’Arriero, D., Lorenzi, S., Moretti, M., and Lovati, A. B. (2020). Independent, controllable stretch-perfusion bioreactor chambers to functionalize cell-seeded decellularized tissues. *Ann. Biomed. Eng.* 48 (3), 1112–1126. doi:10.1007/s10439-019-02257-6

Taylor, D. A., Caplan, A. L., and Macchiarini, P. (2014). Ethics of bioengineering organs and tissues. *Expert Opin. Biol. Ther.* 14 (7), 889–892. doi:10.1517/14712598.2014.915303

Wagner, D. E., Bonvillain, R. W., Jensen, T., Girard, E. D., Bunnell, B. A., Finck, C. M., et al. (2013). Can stem cells be used to generate new lungs? ex vivo lung bioengineering with decellularized whole lung scaffolds. *Respir. Care.* 58 (6), 895–911. doi:10.1111/respcare.12102

Wallis, J. M., Borg, Z. D., Daly, A. B., Deng, B., Ballif, B. A., Allen, G. B., et al. (2012). Comparative assessment of detergent-based protocols for mouse lung decellularization and re-cellularization. *Tissue Eng. Part C Methods* 18 (6), 420–432. doi:10.1089/tenc.2011.0567

Wanz dysert, R., and Dehn, F. (2015). Advanced single-cell technologies to guide the development of bioengineered lungs. *Am. J. Physiol.-Lung Cell. Mol. Physiol.* 320 (6), L1101–L1117. doi:10.1152/ajplung.00089.2021

Weib, E. R. (2015). On the tricks alveolar epithelial cells play to make a good lung. *Am. J. Respir. Crit. Care Med.* 191 (5), 504–513. doi:10.1164/rccm.201409-1660OE

Weiss, D. J., Bates, J. H., Gilbert, T., Wiles, W. C., Latuco, C., Rajagopal, J., et al. (2013). Stem cells and cell therapies in lung biology and diseases: Conference report. *Ann. Am. Thorac. Soc.* 10 (5), 525–544. doi:10.1513/AnnalsATS.201304-0984W

Wilkerson, D. C., Alva-Ortalea, J. A., Suarez, J. M., Vijayaraj, P., Durra, A., Richardson, W., et al. (2017). Development of a three-dimensional bioengineering technology to generate lung tissue for personalized disease modeling. *Stem Cells Transl. Med.* 6 (2), 622–635. doi:10.1002/sctm.2016-0192
